NCT04951492View on ClinicalTrials.gov

Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 9, 2022

Primary Completion Date

October 15, 2023

Study Completion Date

October 15, 2023

Conditions
Castration-Resistant Prostate CarcinomaProstate Adenocarcinoma
Interventions
DRUG

Olaparib

Given PO

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Washington

OTHER